

# **Novartis data finds relapsing MS patients on Gilenya® had greater treatment retention and satisfaction rates vs. injectable DMTs**

Sep 16, 2016

---

**Source URL:** <https://qa1.novartis.us/news/media-releases/novartis-data-finds-relapsing-ms-patients-gilenya-had-greater-treatment-retention-and-satisfaction-rates-vs-injectable-dmts-0>

## **List of links present in page**

1. <https://qa1.novartis.us/news/media-releases/novartis-data-finds-relapsing-ms-patients-gilenya-had-greater-treatment-retention-and-satisfaction-rates-vs-injectable-dmts-0>